

## Executive Summary

### Report to the The Board of Directors

Being Held on 29 June 2021

<b>Subject</b>	<b>CLINICAL RESEARCH NETWORK YORKSHIRE AND HUMBER (CRN Y&amp;H) ANNUAL REPORT (AR) FOR 2020/21</b>
<b>Supporting TEG Member</b>	Sandi Carman, Assistant Chief Executive Officer
<b>Author</b>	Amber O'Malley, Chief Operating Officer
<b>Status<sup>1</sup></b>	A

### PURPOSE OF THE REPORT

To obtain ratification from the STHFT Board of Directors (following approval from the Trust Executive Group on 23 June 2021)

### KEY POINTS

- The Clinical Research Network Yorkshire and Humber (CRN Y&H) is expected to produce an Annual Report (AR) to set out how the network has performed against the CRN Priorities, Local Clinical Research Network (LCRN) Performance Indicators and any local strategic initiatives and projects anticipated to be delivered in year.
- The Clinical Research Network Coordinating Centre (CRNCC) has advised of changes to LCRN reporting and simplified the format for all LCRNs for 2020/21. The 2020/21 AR consists of:
  - (a) a four page summary, designed to capture details of CRN Y&H activities in six key areas and
  - (b) an LCRN Fact Sheet, designed to capture key performance and finance data, co-produced with the CRNCC.
- A condensed version of CRN Y&H activities in the form of the AR cannot adequately capture the exceptional performance, partnership working and commitment from CRN Y&H colleagues and its constituent Partner Organisations in delivering NIHR CRN Portfolio research. The production of the AR has drawn on the significant contribution the region's Partners have made to the Urgent Public Health (UPH), Vaccines and Restart programme, as well as delivery of strategic initiatives that drive the agenda to meet the health and care needs of the region's population.
- Key performance achievements include:
  - A record breaking 170,082 participants recruited into 640 NIHR CRN Portfolio studies (1/15 LCRNs)
  - Delivered 12.2% of the overall recruitment for NIHR CRN as a whole
  - Top recruiting CRN to COVID-19 Vaccine Studies with 3,278 (10.5%) participants across 4 studies
  - Top recruiting CRN to UPH Badged Studies with 132,921 (14.7%) participants across 49 studies
  - Top recruiting CRN to Cancer studies (4,920 Participants), Cardiovascular Disease studies (5,834 Participants), Metabolic & Endocrine Disorders studies (344 Participants) and Trauma & Emergency Care studies (69,772 Participants)

- Despite the pandemic, we have delivered increased recruitment in eight specialties from FY1920 to FY2021 (Cardiovascular Disease, Critical Care, Infection, Mental Health, Ophthalmology, Reproductive Health and Childbirth, Respiratory Disorders, Trauma and Emergency Care)
  - CRN Y&H achieved its best performance for the Participant in Research Experience Survey (PRES) with 2,487 surveys
- Despite the challenges, CRN Y&H has delivered its most successful year to date.

## IMPLICATIONS<sup>2</sup>

AIM OF THE STHFT CORPORATE STRATEGY 2017-2020		TICK AS APPROPRIATE
1	Deliver the Best Clinical Outcomes	√
2	Provide Patient Centred Services	
3	Employ Caring and Cared for Staff	
4	Spend Public Money Wisely	√
5	Deliver Excellent Research, Education & Innovation	√

## RECOMMENDATIONS

The Board of Directors is asked to agree and ratify the 2020/21 CRN Y&H Annual Report
---

## APPROVAL PROCESS

Meeting	Date	Approved Y/N
CRN Y&H Triumvirate; Amber O'Malley, Alistair Hall, Sandi Carman	17/06/2021	Y
CRN Y&H Partnership Group Chair action (following virtual consultation)	22/06/2021	Y
STHFT Trust Executive Group	23/06/2021	Y

<sup>1</sup> Status: A = Approval  
 A\* = Approval & Requiring Board Approval  
 D = Debate  
 N = Note

<sup>2</sup> Against the five aims of the STHFT Corporate Strategy 2017-20

**SHEFFIELD TEACHING HOSPITALS NHS FOUNDATION TRUST**

**THE BOARD OF DIRECTORS**

**29 June 2021**

**CLINICAL RESEARCH NETWORK YORKSHIRE AND HUMBER  
ANNUAL REPORT 2020/21**

**1. INTRODUCTION**

- 1.1. The Clinical Research Network Yorkshire and Humber (CRN Y&H) is expected to produce an Annual Report (AR) to set out how the network has performed against the CRN Priorities, Local Clinical Research Network (LCRN) Performance Indicators and any local strategic initiatives and projects that are included in the Annual Business Plan (ABP) at the start of each financial year.
- 1.2. Given the COVID-19 pandemic and the suspension of the national High Level Objectives in 2020/21 the Clinical Research Network Coordinating Centre (CRNCC) has advised of changes to LCRN reporting and simplified the format for all LCRNs. The 2020/21 AR consists of:
  - (a) a four page summary, designed to capture details of CRN Y&H activities in six areas. It is intended that all LCRN reports will be included in the NIHR CRN Annual Report to the Department of Health and Social Care (DHSC), and;
  - (b) an LCRN Fact Sheet, designed to capture key performance and finance data, co-produced with the CRNCC.
- 1.3. The 2020/21 AR and LCRN Fact Sheet are developed in line with the DHSC/LCRN Host Organisation contract and the accompanying Performance and Operating Framework (POF).
- 1.4. This paper presents the CRN Y&H AR for the Board of Directors for review and approval.

**2. PLANNING PROCESS**

- 2.1. The AR has been prepared by the CRN Y&H Operational Management Group.
- 2.2. The AR can in no way reflect the commitment, hard work, innovation and desire to make a difference from all Partners, stakeholders and citizens across the Yorkshire and Humber region, in what has been an exceptional year.

- 2.3. In preparing the AR the CRN Y&H team has drawn on the significant contribution the region's Partners have made to the Urgent Public Health (UPH), Vaccines research and Restart of the NIHR CRN Portfolio, working collaboratively in partnership and across organisational boundaries. Our engagement work across the region to provide equity of access to clinical research, particularly to those communities adversely affected by COVID-19 has played an important and very central element of CRN activity in 2020/21 and the network as a whole has driven this agenda forward. The flexibility of the CRN workforce and contribution of the Agile Research Team (ART), has enabled NIHR CRN Portfolio studies to be delivered at pace and scale and has been highly successful. Iterative changes resulting from lessons learned during the year have been made and the CRN Y&H is keen to capture and build on this progress into future ways of working.
- 2.4. CRN Y&H has invested in a significant number of strategic initiatives and projects throughout the 2020/21 year. The AR captures a few key themes emerging from this investment.
- 2.5. The AR is supplemented by a high level infographic to capture numerically the achievements of CRN Y&H and its constituent Partners. Please see Appendix 1 for the AR and Appendix 2 for the LCRN Fact Sheet. A public facing CRN Y&H Impact Report is in development and will be shared in due course.

### **3. CRN Y&H KEY ACHIEVEMENTS**

- 3.1 Key performance achievements are outlined in Appendix 1 and the associated infographic.

### **4. MONITORING AND GOVERNANCE ARRANGEMENTS**

- 4.1. There have been considerable changes and increased priorities over the course of the year. CRN Y&H has undertaken daily, weekly, monthly, quarterly and a six monthly review against DHSC/CRNCC priorities as these have emerged and actively engaged with Partners, Specialty Leads and other key stakeholders to monitor, manage and report performance against national plans and priorities.
- 4.2 Attendance at national weekly CRN Leaders meetings, led by the National Chief Executive Officer and fortnightly CRN Operational Delivery meetings, led by the National Chief Operating Officer have supported national and regional discussions. Weekly / fortnightly UPH / Vaccines national meetings have been scheduled and attended by CRN Y&H colleagues to ensure oversight and performance of studies.
- 4.3 Standard as part of the annual business planning and reporting cycle is the performance management of the portfolio of studies and associated activities. These have remained a standing agenda item at the CRN Y&H Operational Management Group, Executive Group and Partnership Group meetings.

- 4.4. CRN Y&H were expected to attend a mid-year and an annual performance review meeting with the CRNCC. The January 2021 mid-year meeting was cancelled due to the pandemic.
- 4.5. The Board of Directors is asked to note that the annual performance review meeting is scheduled to take place on 9 July 2021. This will be attended by members of the CRNCC Executive Team, the CRNCC Senior team link, CRN Y&H Clinical Director and Chief Operating Officer, the Partnership Group Chair and CRN Y&H Host Nominated Executive Director.

## **5. CONCLUSION**

- 5.1. The research community in the Yorkshire and Humber region has risen to the immense challenges of the COVID-19 pandemic. Clinical trials have been planned, set up and delivered effectively at speed, pace and scale, ensuring our local citizens had opportunities to take part in research from the outset.
- 5.2. The CRN Y&H core team and Partner Organisations across the region have successfully delivered and contributed to landmark breakthroughs in research.
- 5.3. Despite the challenges CRN Y&H has delivered its most successful year to date.

## **6. RECOMMENDATION**

- 6.1. The Board of Directors is asked to:
  - Note the achievements and successes of the CRN Y&H
  - Note the annual performance review meeting, scheduled for 9 July 2021
  - Approve the CRN Y&H AR.

**Amber O'Malley**  
**Chief Operating Officer**

**Sarah Clayton**  
**Business and Corporate Governance Lead**

## Appendix 1: CRN Y&H Annual Report 2020/21

### Section 1: CRN Y&H contribution to three Category 1A or Category 1B Priority studies

#### **CPMS 46787: Novavax vaccine trial (WP\*: *Inclusive, Equity of access, Research culture*)**

City-wide vaccine hub model led by Leeds city region (Leeds Teaching Hospitals NHS Trust) and Bradford city region (Bradford Patient Recruitment Centre (PRC)). Key highlights;

- City-wide collaborations including acute sector, community, primary care, patient and public representatives, universities, local councils and CRN Y&H team to ensure maximum reach.
- Speedy trial setup in less than two weeks from receipt of the final protocol to recruitment of the first participant.
- Sports hall model utilised to maximise efficiency and was highly successful.
- Exceptional participant recruitment levels with Leeds hub recruiting 806/15,203 participants and the Bradford hub recruiting 726/15,203 participants. This equates to 11.9% of the overall study recruitment in the UK.
- Significant learning's on delivering research at pace, scale and within a community.
- Vaccine model replicated across Y&H, eight Hubs in total, and all successfully recruiting to COVID-19 vaccines research (CRN Y&H total recruitment 10.5%)

#### **CPMS 47183: AZ monoclonal antibody trial (PROVENT) (WP: *Partnership working*)**

Novel NHS/Social Enterprise collaboration, to rapidly deliver vaccines research. Key highlights;

- The Wakefield hub is a unique collaboration between Mid Yorkshire Hospitals NHS Trust and Spectrum Community Health, a Community Interest Company (CIC).
- Collaboration enabled 'usual' NHS obstacles such as lengthy HR processes and fixed clinical schedules to be overcome at rapid pace to enable speedy recruitment.
- Agile way of working resulted in 1st Global Participant to the trial.
- The Spectrum CIC, Mid Yorkshire Hospitals NHS Trust and the CRN Y&H have since been shortlisted for the Pharmatimes 2021 Clinical Research Site of the Year award.
- Vaccines Task Force infrastructure funding in Spectrum CIC has provided lasting research capacity in this non-NHS setting for the benefit of the Y&H region.

#### **CPMS 12725: The PRIEST Study: Pandemic Respiratory Infection Emergency System Triage. (WP: *Participant-centred*)**

Engagement of Yorkshire Ambulance Service in Covid-19 research. Key Highlights include:

- Total UK 2020/21 study recruitment at 86,071 participants of which 66,315 participants (76%) recruited through Yorkshire Ambulance Service (YAS).
- Significant volume of data collected from 111, 999 and face to face ambulance attendances to assess the effectiveness of triage of patients by these agencies and investigate if poor outcomes were due to ineffective triage. A significant achievement for YAS as the highest recruiting Trust in England in 2020/21.

### Section 2. Challenges recruiting to Urgent Public Health (UPH) Prioritised studies

#### **CRN Y&H Core Team (WP: *Collaborative national working, Consistency, Transparency*)**

- Daily stand up meetings with senior CRN Y&H colleagues across key business functions to ensure clinical, strategic and operational oversight of all UPH/Vaccines/Restart.

- Separate weekly meetings established for Vaccines Hubs to enable oversight, sharing of knowledge, resources, skills and challenges.
- Senior lead designated to each UPH study enabling rapid responses to study team requests, effective liaison with Partners and speedy study set up across all settings.
- Expedited processes for Partners to access funding to increase workforce capacity.

**Partner Engagement** (*WP: Partnership working, Transparency, Responsive to stakeholders*)

- Regular region-wide meetings with CRN Y&H team and Partners, Specialty Leads and other stakeholders to ensure two-way communications, problem solving and share experiences. This was supplemented by regular Partner Bulletins, sharing key messages across network social media channels and regular contact with communications leads in Partner Organisations (POs) to ensure consistent messaging.
- POs/CRN Y&H links established regular meetings to discuss UPH/Vaccines/Restart, vaccine delivery and workforce challenges. Additional support was provided where required such as access to funding and access to Agile Research Team (ART) team resources.

**Research Delivery in Primary Care and other Settings** (*WP: Inclusive, Equity of access*)

- 247 Primary Care (PC) sites recruited to the PRINCIPLE trial (CPMS 45457), there was also involvement in Raptor (CPMS 46023) and VIRUS watch (CPMS 45822). PC has contributed as Participant Identification Centre sites and completed mail outs for a variety of short notice UPH/Vaccine studies showing high levels of cooperation during difficult circumstances.
- Two care homes delivered in the non-NHS sector; VIVALDI (CPMS 45953) was very successful due to the established CRN Y&H ENRICH network, recruiting 452 participants.

**Section 3. Workforce** (*WP: Workforce development, Efficiency, Flexibility*)

**Workforce capacity**

- In addition to PO 1-1 meetings, regional Lead Nurse meetings were held weekly, offering strategic direction, practical problem solving, prioritisation of activities, support, wellbeing and bespoke training e.g. resilience.

**Managing and mitigating the impact of redeployment/staffing shortages**

- Staff availability was compromised due to sickness, redeployment, isolation and staff shielding. To help mitigate against this, CRN Y&H supported Trust staff movement from clinical areas, and retraining to cover areas with high COVID admissions.
- Members of the CRN Y&H ART and core teams retained day to day flexibility to provide resources where most needed.
- Workforce from Mental Health, community and PC supported UPH studies allowing primary and secondary care teams to work collaboratively across organisational boundaries e.g. Moonshot study (Falcon) CPMS 45932.
- Strategic funding secured for workforce projects to explore utilisation of workforce included NHS professionals training at Sheffield Teaching Hospitals NHS Foundation Trust which was expanded in three other Trusts in the region.

**Lessons learned/Future implications.**

- Retaining Partner Organisation knowledge, supporting staff skills, facilitating mentorship/cross organisational working to feed into projects going forward.
- Ensuring diversity across ART, developing new roles of community research nurses to support the South Asian and East European communities.

- Exploring the use of the Calderdale Framework to ensure the correct skill mix within Partner Organisations and sharing lessons learned across the network infrastructure.

**Section 4. Restart and Partner organisation engagement** (WP: Partnership working, Responsive to stakeholders)

- CRN Y&H achieved a restart of 80% for both commercial and non-commercial portfolios.
- CRN Y&H recruited 10.6% of NIHR CRN Portfolio studies of which 7.7% were in UPH studies.
- Restart was largely managed by individual POs and varied considerably depending on their size and the level of vaccine activity. This depended on their own individual circumstances, portfolio size, staff redeployment to clinical service or UPH studies, sickness and reopening of clinical services. All studies were regularly assessed and where necessary, prioritised by local Principal Investigators and study teams.
- Recruitment targets were renegotiated if required due to COVID-19 delays, taking into account the availability of local support services.
- A collaborative Engagement Working Group was established with membership from POs and the CRN Y&H Core Team. This group has developed a local Research Engagement Strategy for delivery in the following financial year.

**Section 5. Patient and Public Involvement and Engagement (PPIE)** (WP: Patient involvement, Participant-centred, Collaborative national working)

- 16 Regional Champions regularly met digitally to support UPH/Vaccines studies.
- They have been instrumental in helping to plan and deliver an ethnic minority focus group, looking at the Oxford Vaccine Study patient pathway, patient information leaflets and commenting on opportunities and challenges for ethnic minority participants. The findings were shared nationally to inform the design of on-going and future vaccine studies.
- Co-producing and co-delivering the 'Acting together to improve health inequalities' event with Champions from CRN North East and North Cumbria, looking at opportunities and challenges about ethnic minority inclusion in research.
- Contributing expert-by-experience advice and using personal community connections to help the CRN Y&H Ethnic Minority Research Inclusion (EMRI) strategic project team to design and deliver ethnic minority virtual outreach, such as webinars for community leaders and NHS staff and to deal with and tackle misinformation about research, targeting ethnic minority communities in the Y&H region.
- In the context of the CRN Y&H Partnership Group, working to review funding allocations for Partner Organisation strategic initiatives, particularly to support COVID-19 research.
- Supporting a number of NIHR CRN advisory and working groups including the NIHR CRN UPH studies advisory group; "Covid Connect" discussions with NIHR CRN Specialty leads/senior managers; developing the CRN NIHR PC Strategy; participating in national webinars, e.g. the annual NIHR Life Sciences Industry event, and public engagement /learning videos, e.g. videos featured in the Future Learn Course "COVID-19: Understanding the research behind the pandemic".
- CRN Y&H achieved its best performance for the PRES survey with 2,487 surveys completed (1,428 paper and 1,059 digital), with 19/22 NHS Trusts participating. These




results showed that front-line research delivery staff achieved excellent participant satisfaction rates despite challenging conditions due to the pandemic.

**Section 6. Selected non-COVID-19 LCRN achievement** (WP: Good governance, Effectiveness, Efficiency, Responsive to stakeholders, Equality of access, Participant-centred)

- CRN Y&H had its best year to date, recruiting a total of 170,082 participants (12.2%) across 640 studies. A large proportion was to vaccine and UPH studies with 3,278 (10.6%) and 132,921 participants (14.7%) respectively.
- Despite the COVID-19 challenges eight specialties (Cardiovascular, Critical Care, Infection, Mental Health, Ophthalmology, Reproductive Health & Childbirth, Respiratory and Trauma & Emergency Care) increased recruitment in comparison to 2019/20.
- Restructure of CRN Y&H engagement strategies to operate across place based and ICS geographies with a broad range of Partners and stakeholders
- Partners actively engaged in leading and contributing to multiple regional working groups e.g. EMRI Project Group, Strategic Clinical Leaders Group, Funding Working Group.
- Local Partner Survey (replicating the national Partner Survey) resulted in an increased median satisfaction score of 4 in 2019/20 to 12.5 (out of a possible 15), a significant increase and best performance to date.
- CRN Y&H has progressed internal business improvement projects across all areas of the network, e.g. established a performance management framework, improved visibility and efficiency of contracting processes, restructured financial plans to support visibility and clarity for Partners, improved and embedded an effective project management function.
- CRN Y&H made significant investments in strategic initiatives, supporting 35 projects overall which covered a diverse range of areas, reflecting the priorities of the CRN. Key themes and achievements include:
  - Underserved Communities: Development of public facing videos highlighting the benefits of COVID-19 research particularly within ethnic minority communities which achieved national media coverage. CRN Y&H also supported an inclusive approach to disseminating information about Covid vaccinations to hard to reach community groups as well as developing specialist research nurse roles to support research participation from ethnic minority communities and other under-represented patient groups.
  - Early Career Researcher (ECR) Development: CRN Y&H have created a developmental role for Community Trust research nursing in the NIHR Patient Recruitment Centre as well as developing AHP ECR in local MSK services. This includes collaboration with the Leeds Long-Covid pathway team, and developing research plans with MSK physiotherapists.
  - Innovation in Research:
    - CRN Y&H supported development of the pan-Yorkshire Obesity Research Alliance (YORA) by developing a regional applied obesity research network and strategic action plan through an embedded ECR.
    - CRN Y&H has accelerated the setup of the Wakefield Health and Care Research Hub and a number of collaborative projects that will help both shape and develop cross-organisational working and Hub research activity.

- CRN Y&H has provided further support to the Born in Bradford studies to establish the feasibility of linking primary care NHS dental records to the three Bradford based birth cohorts.
- A public health and communities research practice hub at Leeds Beckett University has been developed which has established a cadre of future collaborators.



## Appendix 2: CRN Y&H Fact Sheet 2020/21

Year	Initial Allocation (1)	(Underspends) (2)	Additional Funding Awarded (3)	Final Expenditure (4)
2014/15	£29,758,177	(£31,292)	£0	£29,726,885
2015/16	£28,908,512	£0	£0	£28,908,512
2016/17	£27,609,575	£0	£36,567	£27,646,142
2017/18	£25,951,709	£0	£6,818	£25,958,527
2018/19	£26,076,175	(£286)	£43,000	£26,118,889
2019/20	£ 25,943,021	(£38,609)	£ 15,000	£25,919,412
2020/21 (5)	£25,862,776	£212	£387,030	£26,250,018

Note (1) Initial core funding allocation including Research Capability Funding excluding top-sliced

Note (2) Underspends reported in the Financial year

Note (3) Additional funding awarded includes ETC Service funding for 2018/19, non-supported study and social care funding for 2019/20, Urgent Public Health (UPH) and Non UPH funding for 2020/21

Note (4) Initial Allocation + (Underspends) + Additional Funding Awarded in-year = Final Expenditure, i.e. the final expenditure for the Financial Year.

Note (5) Allocations include Core funding, ETC Service funding and Public Health Prevention funding excluding top-sliced and Vaccine Taskforce (VTF) 'pump prime' funding. Details of the VTF 'pump prime' funding can be found in Table 7.

Year	Acute	Ambulance	Community Care / Mental Health	Primary care	Corporate Support services costs / Leadership and Management (2)	Other	Total
2014/15	£23,946,414	£62,756	£1,594,694	£1,054,836	£3,068,185	£0	£29,726,885
2015/16	£22,138,605	£98,729	£1,706,434	£1,456,746	£3,507,998	£0	£28,908,512
2016/17	£21,235,896	£103,956	£1,538,451	£1,537,413	£3,230,426	£0	£27,646,142
2017/18	£19,997,169	£116,311	£1,619,144	£1,517,547	£2,708,356	£0	£25,958,527
2018/19	£19,102,592	£110,613	£1,721,364	£1,293,722	£3,806,350	£84,248	£26,118,889
2019/20	£19,722,988	£77,207	£1,719,781	£887,628	£3,438,027	£73,781	£25,919,412
2020/21 (3)	£21,350,600	£134,747	£1,974,412	£471,814	£2,113,248	£205,197	£26,250,018
2020/21 %	81.3%	0.5%	7.5%	1.8%	8.1%	0.8%	100.0%
3 year average (4)	£20,058,727	£107,522	£1,805,186	£884,388	£3,119,208	£121,075	£26,096,106
3 year average %	76.9%	0.4%	6.9%	3.4%	12.0%	0.5%	100.0%

Note (1) The total should equal that of the Final Expenditure column in Table 1 'LCRN Funding'

Note (2) Corporate Support Services costs and Leadership and Management should include host costs only. Delivery will be included in Acute.

Note (3) The 2020/21 sector spend excludes Vaccine Taskforce (VTF) 'pump prime' funding

Note (4) The 3 year average is the mean of the 2018/19 to 2020/21 data, inclusive

Table 3. Contract Type Spend					
Year	LCRN Host Contract (1)	Category A Partners	Category B Partners	Category C Partners	Total (2)
2014/15	£6,261,776	£22,701,723	£763,386	N/A	£29,726,885
2015/16	£6,554,710	£21,507,723	£846,079	N/A	£28,908,512
2016/17	£6,343,099	£20,528,387	£774,656	N/A	£27,646,142
2017/18	£5,901,090	£19,343,381	£714,056	£0	£25,958,527
2018/19	£5,301,015	£19,998,329	£637,896	£181,648	£26,118,889
2019/20	£5,779,016	£19,484,300	£446,641	£209,455	£25,919,412
2020/21	£5,773,291	£19,991,472	£401,441	£83,814	£26,250,018
2020/21 %	22.0%	76.2%	1.5%	0.3%	100.0%
3 year average	£5,617,774	£19,824,700	£495,326	£158,306	£26,096,106
3 year average %	21.5%	76.0%	1.9%	0.6%	100.0%

Note (1) LCRN Host Contract should include spend for the whole host trust, including Delivery.

Note (2) The total should equal the total column in Table 2 "Sector Spend".

Table 4. LCRN Cost Per Weighted Recruit by Financial Year/ Sector (1)							
Year	Acute	Ambulance	Care / Mental Health	Primary care	LCRN Host	Other	Aggregate (2)
2014/15	£126.69	n/a	£96.98	£37.18	n/a	n/a	£101.02
2015/16	£115.17	£7.33	£73.02	£54.26	n/a	n/a	£92.61
2016/17	£85.64	£7.88	£75.01	£73.19	n/a	n/a	£85.87
2017/18	£75.88	£25.88	£52.87	£111.42	n/a	n/a	£82.32
2018/19	£79.07	£27.84	£37.49	£22.17	n/a	£13.12	£73.32
2019/20	£71.55	£28.15	£44.77	£16.68	n/a	£28.79	£69.57
2020/21	£156.23	£1.98	£133.66	£35.48	n/a	£5.27	£96.61

Note (1) Excludes participants recruited to commercial studies. Expenditure excludes national Top-sliced funding.

Note (2) The Aggregate figure is based upon total expenditure divided by total weighted recruitment.

Table 5. Weighted Recruitment (WR) data- For info only								
	Acute	Ambulance	Care / Mental Health	Primary care	LCRN Host (1)	Other	Total	Corrected Total WR from table 6
2014/15 Check	189,019	-	16,444	28,369	-	-	233,831	235,767
2015/16 Check	192,220	13,469	23,369	26,848	-	-	255,906	263,031
2016/17 Check	247,957	13,192	20,510	21,005	-	-	302,664	308,529
2017/18 Check	263,537	4,494	30,624	13,620	-	-	312,275	315,322
2018/19 Check	241,581	3,973	45,915	58,367	-	6,420	356,255	356,255
2019/20 Check	275,649	2,743	38,412	53,226	-	2,563	372,592	372,592
2020/21 Check	136,659	68,018	14,772	13,298	-	38,970	271,717	271,716

Note (1) No recruitment is attributed to the LCRN Host - it would all be included within the Sector of the Host, which is usually Acute.

FY 14/15 Total Recruitment (Excludes Commercial)	FY 14/15 Total non commercial Weighted Recruitment	FY 15/16 Total Recruitment (Excludes Commercial)	FY 2015/16 Total Weighted Recruitment	FY 16/17 Total Recruitment (Excludes Commercial)	FY 2016/17 Total Weighted Recruitment	FY 17/18 Total Recruitment (Excludes Commercial)	FY 2017/18 Total Weighted Recruitment
53,807	235,767	56,796	263,031	72,039	308,529	79,647	315,322

FY 18/19 Total Unweighted Recruitment (Excludes Commercial) (1)	FY 2018/19 Total Weighted Recruitment (1)	FY 19/20 Total Unweighted Recruitment (Excludes Commercial) (1)	FY 2019/20 Total Weighted Recruitment (1)	FY 20/21 Total Unweighted Recruitment (Excludes Commercial) (1)	FY 2020/21 Total Weighted Recruitment (1)
88,307	356,255	68,294	372,592	167,003	271,716

Note (1) Unweighted and Weighted Recruitment Totals for FY 2020/21 will be provided by the CRNCC on around 30 April, dependent on when the year-end data cut becomes available.

Year	Total Allocation (1)	(Underspends) (2)	Final Expenditure (3)
2020/21	£767,685	£0	£767,685

Note (1) Total Vaccine Taskforce (VTF) pump-prime funding awarded in 2020/21.

Note (2) Underspends reported in the Financial year.

Note (3) Total Allocation + (Underspends) = Final Expenditure, i.e. the final expenditure for the Financial Year.

Population	5,560,334 (2021)
Number of Category A Partners (including Host Organisation)	25
Number of Category B Partners	43
Number of Category C Partners	386
Recruitment per 1000 population	30.6

<b>LCRN Category A Partners (including Host Organisation)</b>		
<b>Partner Name</b>	<b>Organisation Data Service (ODS) Code</b>	<b>Sector</b>
Airedale NHS Foundation Trust	RCF	Acute
Barnsley Hospital NHS Foundation Trust	RFF	Acute
Bradford District Care NHS Foundation Trust	TAD	Mental Health
Bradford Teaching Hospitals NHS Foundation Trust	RAE	Acute
Calderdale and Huddersfield NHS Foundation Trust	RWY	Acute
Doncaster and Bassetlaw Hospitals NHS Foundation Trust	RP5	Acute
Harrogate and District NHS Foundation Trust	RCD	Acute
Hull University Teaching Hospitals NHS Trust	RWA	Acute
Humber NHS Foundation Trust	RV9	Community Care
Leeds and York Partnership NHS Foundation Trust	RGD	Mental Health
Leeds Community Healthcare NHS Trust	RY6	Community Care
Leeds Teaching Hospitals NHS Trust	RR8	Acute
Mid Yorkshire Hospitals NHS Trust	RXF	Acute
Northern Lincolnshire and Goole Hospitals NHS Foundation Trust	RJL	Acute
Rotherham, Doncaster & South Humber NHS Foundation Trust	RXE	Mental Health
Sheffield Children's NHS Foundation Trust	RCU	Acute
Sheffield Health & Social Care NHS Foundation Trust	TAH	Mental Health
Sheffield Teaching Hospital NHS Foundation Trust	RHQ	Acute
South West Yorkshire Partnership NHS Foundation Trust	RXG	Mental Health
The Rotherham NHS Foundation Trust	RFR	Acute
York and Scarborough Teaching Hospital NHS Foundation Trust	RCB	Acute
Yorkshire Ambulance Service NHS Trust	RX8	Ambulance
University of Sheffield	10007157	University
University of Leeds	10007795	University

<b>Other NIHR Infrastructure and Academic Health Science Network</b>	
<b>Academic Health Science Network (AHSN)</b>	Yorkshire & Humber AHSN
<b>Applied Research Collaboration (ARC)</b>	NIHR ARC Yorkshire and Humber
<b>Biomedical Research Centres (BRCs)</b>	NIHR Leeds Biomedical Research Centre - Musculoskeletal NIHR Sheffield Biomedical Research Centre - Neurology
<b>Clinical Research Facilities (CRFs)</b>	NIHR Leeds Clinical Research Facility NIHR Sheffield Clinical Research Facility
<b>Experimental Cancer Medicine Centre (ECMC)</b>	NIHR Leeds Experimental Cancer Medicine Centre NIHR Sheffield Experimental Cancer Medicine Centre
<b>Medtech and In vitro diagnostic Co-operatives (MICs)</b>	NIHR Children and Young People Medtech Cooperative NIHR Devices for Dignity Medtech Cooperative NIHR Leeds In Vitro Diagnostics Cooperative NIHR Surgical Metech Cooperative
<b>Patient Recruitment Centre (PRCs)</b>	NIHR Patient Recruitment Centre: Bradford
<b>Patient Safety Translational Research Centres (PSTRCs)</b>	NIHR Yorkshire and Humber Patient Safety Translational Research Centre